Neuronetics Stock News

Neuronetics (STIM) delivered earnings and revenue surprises of 12.12% and 2.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • Babcock & Wilcox (NYSE: BW ) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million. • Desktop Metal (NYSE: DM ) is projected to report quarterly loss at $0.09 per share on revenue of $49.58 million. • Stevanato Group (NYSE: STVN ) is projected to report quarterly earnings at $0.11 per share on revenue of $244.99 million. • CPI Card (NASDAQ: PMTS ) is likely to report quarterly earnings at $0.35 per share on revenue of $94.40 million. • CareMax (NASDAQ: CMAX ) is likely to report quarterly loss at $0.06 per share on revenue of $118.44 million. • Matinas BioPharma Hldgs (AMEX: MTNB ) is expected to report quarterly loss at $0.03 per share on revenue of $470.00 thousand. • Nuvei (NASDAQ: NVEI ) is likely to report quarterly earnings at $0.57 per share on revenue of $264.56 million. • Gaotu Techedu (NYSE: GOTU ) is likely to report quarterly earnings at $0.26 per share on revenue of $333.80 million. • OptiNose (NASDAQ: OPTN ) is estimated to report quarterly loss at $0.

MALVERN, Pa., March 03, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM ), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the launch of their new campaign to increase awareness of the impact of depression on millions of people. The campaign is called "Tap into a New Possibility" and illustrates how overwhelmed patients with major depressive disorder (MDD) feel about managing their condition, especially if they have not benefited from multiple treatment attempts. "Too many people are suffering, and traditional treatments don''t work for everyone. It''s critical that … Full story available on Benzinga.com

MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve th

Neuronetics (STIM) amended its term loan agreement with its current lenders, investment affiliates managed by SLR Investment which was originally entered into on Mar.2, 2020 and amended

Major neurostimulation devices market players include Abbott, Boston Scientific, IntraPace, Laborie, LivaNova, Medtronic, Neuronetics, SPR Therapeutics, Cyberonics, ElectroCore Inc., Aleva Neurotherapeutics SA, Synapse Biomedical Inc., MicroTransponder, RS Medical, Helbling holding Ag, EndoStim Inc., and BioControl Medical. SELBYVILLE, Del. , Jan. 20, 2022 /PRNewswire/ -- The neurostimulation devices market size is anticipated to record a valuation of USD 13.6 billion by 2027, according to the most recent study by Global Market Insights Inc. Increasing adoption and introduction of advanced neurostimulation devices will drive the overall market growth. Increasing demand for minimally invasive surgeries in developed countries attributed to the rising preference among patients for shorter hospital stays and faster recovery will accelerate the neurostimulation devices market expansion. Neurological patients using minimally invasive techniques, have experienced reduced treatment costs, less pain, and speedy recovery.

The stock price of Neuronetics Inc (NASDAQ: STIM) increased by 14.89% in the most recent trading session. This is why it happened.

Neuronetics <> expects Q4 total revenue in the range of approximately $14.5M to $15M vs. previously stated guidance of $13M to $14M and consensus of $13.48M

MALVERN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM ), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is named Top Neuromodulation Solution Provider in 2021 by MedTech Outlook magazine. NeuroStar is the leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder. With over 4.3 million treatments delivered and countless lives transformed, a recent publication shows that NeuroStar achieved a high response rate of 83% and remission rate of 62% (Sackeim, et al). "We are grateful to be recognized as a leader in the neuromodulation space," said Keith J. Sullivan, President Full story available on Benzinga.com

3 biotech penny stocks to watch after Bellus Health (BLU) skyrockets. The post Biotech Penny Stocks To Buy After BLU Stock Explodes?

Symposium to Highlight Worlds Largest Depression Outcomes Registry Symposium to Highlight Worlds Largest Depression Outcomes Registry

Invesco Ltd. purchased a new position in Neuronetics, Inc. (NASDAQ:STIM) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 230,383 shares of the companys stock, valued at approximately $3,691,000. A number of other hedge funds and other institutional investors also recently added to []

State Street Corp bought a new stake in shares of Neuronetics, Inc. (NASDAQ:STIM) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 379,836 shares of the company’s stock, valued at approximately $6,085,000. State Street Corp owned about 1.44% of Neuronetics at the end of the most recent […]

Shares of Neuronetics, Inc. (NASDAQ:STIM) have received a consensus recommendation of “Hold” from the six analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price […]

Neuronetics, Inc. (NASDAQ:STIM) Director Robert Cascella purchased 15,000 shares of the businesss stock in a transaction dated Monday, November 22nd. The stock was purchased at an average price of $4.10 per share, for a total transaction of $61,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available []